BBIO Live signals | Maximize Profits with Getagraph.com

SELL 25854 min ago

@ $28.73

Issued: 8 Apr 2024 @ 09:34

Return: -15.32%

Previous signal: Apr 4 - 11:18

Previous signal: Buy

Return: -1.44 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	1.70M
Average Volume	1.69M
Market Cap	4.49B
EPS	$0 ( 2024-02-22 )
Next earnings date	( $-0.400 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.16
ATR14	$0.0360 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-12	Kumar Neil	Buy	313 588	Restricted Stock Units
2024-03-12	Kumar Neil	Buy	45 140	Stock Option (right to buy)
2024-03-12	Stephenson Brian C	Buy	107 278	Restricted Stock Units
2024-03-12	Stephenson Brian C	Buy	15 442	Stock Option (right to buy)
2024-03-01	Scott Randal W.	Sell	2 500	Common Stock

INSIDER POWER
-18.21
Last 100 transactions
Buy: 1 673 575 \| Sell: 2 657 073

Volume Correlation

Long: 0.14 (neutral)

Short: 0.62 (weak)

Signal:(46.497) Neutral

BridgeBio Pharma Inc Correlation

10 Most Positive Correlations
NVTS	0.941
ALTR	0.941
MCAA	0.929
ANSS	0.928
RCEL	0.925
NVDA	0.924
ALXN	0.923
PLYA	0.923
PDFS	0.923
GXII	0.92

10 Most Negative Correlations
NAKD	-0.928
NCBS	-0.922
GSMG	-0.921
PIXY	-0.913
SNGX	-0.911
LAWS	-0.911
GOOD	-0.908
VWE	-0.907
TSHA	-0.907
TRIT	-0.905

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BridgeBio Pharma Inc Correlation - Currency/Commodity

-0.18
( neutral )

0.28
( neutral )

0.00
( neutral )

-0.58
( weak negative )

-0.57
( weak negative )

-0.31
( neutral )

BridgeBio Pharma Inc Financials

Annual	2023
Revenue:	$9.30M
Gross Profit:	$6.86M (73.71 %)
EPS:	$-3.95

FY	2023
Revenue:	$9.30M
Gross Profit:	$6.86M (73.71 %)
EPS:	$-3.95

FY	2022
Revenue:	$77.65M
Gross Profit:	$74.21M (95.58 %)
EPS:	$-3.35

FY	2021
Revenue:	$69.72M
Gross Profit:	$66.60M (95.53 %)
EPS:	$-4.77

Financial Reports:

No articles found.

BridgeBio Pharma Inc

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.